We address this complexity to transform drug development
News
Mon Oct 11 2021biotx.ai's COVID-19 strategy is to find patterns linked to the disease in the genomes of patients as well as in the DNA of the virus itself. This process takes time, and the limiting factor is the rate at which the data becomes available.
Trusted Partners
40%
Faster than traditional
drug development.
0
Wetlab experiments. Patients needed until P2.
20%
Better models than
PRS.
7
Assets currently in development in pipeline.
Wide Data vs. Big Data
Why proven machine learning approaches fail at deciphering the human genome
Our Team
The People Behind Our Tech
Meet the innovators on the forefront of biomedical AI research
Pipeline
Novel COVID-19 Treatment
See what discoveries we’re making
and where we’re heading
Solutions
Beyond Drug Development
Drug target linkage, patient stratification and predictive diagnostics
Newsroom
See What We’ve Been Up To
Mon Oct 04 2021
Treatment for COVID-19 Ready for Clinical Trials Phase 2b
Our treatment aims to prevent the dangerous overreaction of the immune system that results in patients becoming critically ill due to COVID-19. Using Biobank data, we identified CDK6 as a drug target. Inhibiting it will lower neutrophil cell count, which, when too high, is strongly linked with the severe and critical course of COVID-19. This potential treatment has been endorsed by Key Opionion Leaders from Harvard Medical School, Germany’s Robert-Koch-Institute and the University of Marburg. We are preparing a clinical phase 2b trial to show efficacy.
Tue Oct 05 2021
Biotx BEYOND Webinar 2
In our latest webinar we discuss the future of clinical trials. John Zibert, CEO of Studies&Me talks about how his company conducts decentralized, virtual clinical trials. Our own Justin Cope then presents the technology behind biotx.ai, which is able to discover drug targets with a high likelihood of success in clinical trials.
